Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03070392 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
A Phase 2 study of Uveal Melanoma, sponsored by Immunocore.
- Completed
- Registry status
- Phase 2
- Development phase
- 378
- Enrollment target
- 20
- Study locations
NCT03070392 is a Phase 2 study of Uveal Melanoma that has completed, run by Immunocore. The registered enrollment target is 378 participants, above the 132-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (186% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT03070392, a Phase 2 study of Uveal Melanoma, has completed, sponsored by Immunocore.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 378 participants
- Enrollment target
- 20
- Study locations
Study Summary
To evaluate the overall survival of HLA-A\*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- BIOLOGICAL Ipilimumab
- DRUG Dacarbazine
- BIOLOGICAL IMCgp100
Study Locations (20)
California
- UCLA Medical Center - Los Angeles
- The Angeles Clinic and Research Institute - Los Angeles
- Byers Eye Institute, Stanford University - Palo Alto
- California Pacific Medical Center - San Francisco
New York
- Roswell Park Cancer Institute - Buffalo
- Columbia University Medical Center - New York
- Memorial Sloan Kettering Cancer Center - New York
Illinois
- Northwestern University - Chicago
- The University of Chicago Medicine - Chicago
Massachusetts
- Massachusetts General Hospital - Boston
- Dana Farber Cancer Institute - Boston
Colorado
- University of Colorado - Aurora
Florida
- University of Miami - Sylvester Comprehensive Cancer Center - Miami
Georgia
- Winship Cancer Institute of Emory University - Atlanta
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 378 participants |
| Start Date | 2017-10-16 |
| Est. Completion | 2025-09-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03070392
The ClinicalTrials.gov registry entry for NCT03070392 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 378 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 132-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (186% higher). The listed sponsor is Immunocore, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Uveal Melanoma appearing as the primary indexed condition, and to 4 interventions - of which Pembrolizumab is the first listed.
NCT03070392 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, New York, Illinois.
Frequently Asked Questions
What is clinical trial NCT03070392 about?
NCT03070392 is a clinical study titled "Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma". To evaluate the overall survival of HLA-A\*0201 positive adult patients with previously untreated advanced UM receiving IMCgp100 compared to Investigator's Choice of dacarbazine, ipilimumab, or pembrolizumab.
What is the current status of trial NCT03070392?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 378 participants. The study started on 2017-10-16. Estimated completion is 2025-09-17.
What conditions does trial NCT03070392 study?
This clinical trial studies the following conditions: Uveal Melanoma.
What interventions are being tested in trial NCT03070392?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), Dacarbazine (DRUG), IMCgp100 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03070392?
This trial is sponsored by Immunocore, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03070392 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
RECRUITING · Phase 2
-
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Adjuvant Quisinostat in High-Risk Uveal Melanoma
RECRUITING · Phase 2
-
Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy
ACTIVE NOT RECRUITING · Phase 2
-
(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.